MA46361A - Traitement du cancer de la prostate - Google Patents

Traitement du cancer de la prostate

Info

Publication number
MA46361A
MA46361A MA046361A MA46361A MA46361A MA 46361 A MA46361 A MA 46361A MA 046361 A MA046361 A MA 046361A MA 46361 A MA46361 A MA 46361A MA 46361 A MA46361 A MA 46361A
Authority
MA
Morocco
Prior art keywords
treatment
prostate cancer
prostate
cancer
Prior art date
Application number
MA046361A
Other languages
English (en)
Inventor
Brendan Mark Johnson
David B Maclean
Paul N Mudd Jr
Vijaykumar Reddy Rajasekhar
Lynn Seely
Original Assignee
Myovant Sciences Gmbh
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60915459&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA46361(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Myovant Sciences Gmbh, Takeda Pharmaceuticals Co filed Critical Myovant Sciences Gmbh
Publication of MA46361A publication Critical patent/MA46361A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA046361A 2016-09-30 2017-09-29 Traitement du cancer de la prostate MA46361A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662402004P 2016-09-30 2016-09-30
US201662402150P 2016-09-30 2016-09-30

Publications (1)

Publication Number Publication Date
MA46361A true MA46361A (fr) 2021-03-31

Family

ID=60915459

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046361A MA46361A (fr) 2016-09-30 2017-09-29 Traitement du cancer de la prostate

Country Status (21)

Country Link
US (7) US10449191B2 (fr)
EP (2) EP3518932B1 (fr)
JP (1) JP7062673B2 (fr)
CN (1) CN110248661A (fr)
AU (2) AU2017334035B2 (fr)
BR (1) BR112019006228A2 (fr)
CA (1) CA3038875A1 (fr)
DK (1) DK3518932T3 (fr)
ES (1) ES3002857T3 (fr)
FI (1) FI3518932T3 (fr)
HR (1) HRP20241740T1 (fr)
HU (1) HUE070578T2 (fr)
IL (3) IL308528A (fr)
LT (1) LT3518932T (fr)
MA (1) MA46361A (fr)
MX (2) MX2019003733A (fr)
NZ (1) NZ752918A (fr)
PL (1) PL3518932T3 (fr)
PT (1) PT3518932T (fr)
SI (1) SI3518932T1 (fr)
WO (1) WO2018060463A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3415517T (pt) 2012-09-28 2022-05-13 Takeda Pharmaceuticals Co Forma cristalina de 1-(4-1-(2,6-difluorobenzil)-5- dimetilaminometil-3-(6-metoxipiridazin-3-il)-2,4-dioxo- 1,2,3,4-tetrahidrotieno(2,3-d)-pirimidin-6-il)fenil)-3- metoxiureia
EP3518932B1 (fr) 2016-09-30 2024-11-13 Sumitomo Pharma Switzerland GmbH Traitement du cancer de la prostate
ES2912929T5 (en) 2016-09-30 2025-05-09 Sumitomo Pharma Switzerland Gmbh Methods of treating uterine fibroids and endometriosis
CN110194776B (zh) * 2019-06-27 2021-05-28 四川伊诺达博医药科技有限公司 一种瑞卢戈利的合成方法
CN115279769A (zh) 2019-10-10 2022-11-01 梦欧文科学有限责任公司 N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n’-甲氧基脲的结晶形式
EP4041738A1 (fr) * 2019-10-10 2022-08-17 Myovant Sciences GmbH Formes cristallines solvatées de n-(4-(1-(2,6-difluorobenzyle)-5- ((diméthylamino)méthyle)-3-(6-méthoxy-3-pyridazinyle)-2,4-dioxo -1,2,3,4-tétrahydrothiéno[2,3-d]pyrimidine-6-yl) phényle)-n'-méthoxyurée
CA3185151A1 (fr) 2020-05-29 2021-12-02 Myovant Sciences Gmbh Formes posologiques orales solides combinees d'antagonistes de l'hormone de liberation de la gonadotropine
EP4232164A4 (fr) * 2020-10-20 2025-01-15 Baylor College of Medicine Marqueurs métaboliques multiplexes dans le plasma pour la détection précoce du cancer de la prostate chez les afro-américains
EP4243829A1 (fr) * 2020-11-11 2023-09-20 Myovant Sciences GmbH Méthodes d'administration du rélugolix
EP4419530A1 (fr) 2021-10-18 2024-08-28 Sumitomo Pharma Switzerland GmbH Forme cristalline d'un solvate d'éthanol de n-(4-(1-(2,6-difluorobenzyle)-5-((diméthylamino)méthyle)-3-(6-méthoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tétrahydrothiéno[2,3-d]pyrimidin-6-yl)phényle)-n'-méthoxyurée
WO2023152611A1 (fr) * 2022-02-11 2023-08-17 Aragon Pharmaceuticals, Inc. Apalutamide et relugolix pour le traitement du cancer de la prostate

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2710637B1 (fr) 1993-09-28 1995-12-08 Roquette Freres Mannitol pulvérulent de friabilité modérée et son procédé de préparation.
RU2233284C2 (ru) 1999-03-24 2004-07-27 Такеда Кемикал Индастриз, Лтд. Тиенопиримидиновые производные, способ их получения, фармацевтическая композиция и способ антагонизации гонадотропин-рилизинг гормона
TWI225863B (en) 1999-03-24 2005-01-01 Takeda Chemical Industries Ltd Thienopyrimidine compounds, their production and use
WO2001064683A1 (fr) 2000-02-29 2001-09-07 Takeda Chemical Industries, Ltd. Procedes de production de derives de thienopyramidine
WO2003057689A1 (fr) 2002-01-02 2003-07-17 Fujisawa Pharmaceutical Co., Ltd. Composes aminopyrimidine, procedes de preparation de ces composes et compositions pharmaceutiques les contenant
WO2003064429A1 (fr) 2002-01-30 2003-08-07 Takeda Chemical Industries, Ltd. Thienopyrimidines, procedes de fabrication et d'utilisation correspondants
PL208114B1 (pl) 2002-02-26 2011-03-31 Astrazeneca Ab Kompozycja farmaceutyczna, sposób jej wytwarzania i zastosowanie
PT1591446E (pt) 2003-01-29 2013-06-12 Takeda Pharmaceutical Compostos de tienopirimidina e sua utilização
CA2531508C (fr) 2003-07-07 2013-10-08 Neurocrine Biosciences, Inc. Derives de pyrimidine-2, 4-dione utilises comme antagonistes du recepteur d'hormone liberant de la gonadotrophine
KR20080041662A (ko) 2005-07-22 2008-05-13 다케다 야쿠힌 고교 가부시키가이샤 조기 배란 예방제
NZ580457A (en) 2007-04-06 2012-03-30 Neurocrine Biosciences Inc Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
US8765948B2 (en) 2007-11-07 2014-07-01 Neurocrine Biosciences, Inc. Processes for the preparation of uracil derivatives
TWI442932B (zh) 2008-02-11 2014-07-01 Ferring Int Ct Sa 以ＧｎＲＨ拮抗劑治療攝護腺癌的方法
WO2010026993A1 (fr) 2008-09-03 2010-03-11 武田薬品工業株式会社 Procédé pour améliorer la capacité d'une préparation à être absorbée et préparation dont la capacité à être absorbée est améliorée
PT3415517T (pt) 2012-09-28 2022-05-13 Takeda Pharmaceuticals Co Forma cristalina de 1-(4-1-(2,6-difluorobenzil)-5- dimetilaminometil-3-(6-metoxipiridazin-3-il)-2,4-dioxo- 1,2,3,4-tetrahidrotieno(2,3-d)-pirimidin-6-il)fenil)-3- metoxiureia
EP3185881B1 (fr) 2014-08-26 2022-03-09 Betanien Hospital Méthodes, agents et compositions pour le traitement d'états inflammatoires
FI3263110T3 (fi) 2015-02-26 2023-07-25 Takeda Pharmaceuticals Co Tabletti, joka käsittää metoksiureajohdannaista ja mannitolipartikkeleita
US9949974B2 (en) 2015-09-01 2018-04-24 Abbvie Inc. Methods of adminstering elagolix
US20180044977A1 (en) 2016-08-12 2018-02-15 Raynor Mfg. Co. Rolling door construction for controlling air leakage
EP3518932B1 (fr) 2016-09-30 2024-11-13 Sumitomo Pharma Switzerland GmbH Traitement du cancer de la prostate
ES2912929T5 (en) 2016-09-30 2025-05-09 Sumitomo Pharma Switzerland Gmbh Methods of treating uterine fibroids and endometriosis

Also Published As

Publication number Publication date
US20200129507A1 (en) 2020-04-30
BR112019006228A2 (pt) 2019-06-18
IL265697A (en) 2019-05-30
LT3518932T (lt) 2025-02-10
WO2018060463A3 (fr) 2018-05-11
US12144809B1 (en) 2024-11-19
US20250332166A1 (en) 2025-10-30
US20190224196A1 (en) 2019-07-25
IL308528A (en) 2024-01-01
CN110248661A (zh) 2019-09-17
MX2019003733A (es) 2019-09-26
US10449191B2 (en) 2019-10-22
US20240358700A1 (en) 2024-10-31
US10786501B2 (en) 2020-09-29
US20250082632A1 (en) 2025-03-13
ES3002857T3 (en) 2025-03-07
IL300071A (en) 2023-03-01
EP3518932A2 (fr) 2019-08-07
AU2017334035B2 (en) 2022-11-24
AU2023201047B2 (en) 2025-04-03
JP7062673B2 (ja) 2022-05-06
US11583526B2 (en) 2023-02-21
AU2017334035A1 (en) 2019-05-16
AU2023201047A1 (en) 2023-03-23
WO2018060463A2 (fr) 2018-04-05
FI3518932T3 (fi) 2025-02-03
US12336990B2 (en) 2025-06-24
MX2023001468A (es) 2023-03-03
SI3518932T1 (sl) 2025-03-31
IL265697B1 (en) 2023-03-01
EP3518932B1 (fr) 2024-11-13
IL265697B2 (en) 2023-07-01
US12097198B2 (en) 2024-09-24
US20250057839A1 (en) 2025-02-20
EP4520398A2 (fr) 2025-03-12
US20210205303A1 (en) 2021-07-08
HRP20241740T1 (hr) 2025-02-28
US20220401443A1 (en) 2022-12-22
EP4520398A3 (fr) 2025-04-02
NZ752918A (en) 2022-09-30
DK3518932T3 (da) 2025-01-27
JP2019529574A (ja) 2019-10-17
PL3518932T3 (pl) 2025-04-07
CA3038875A1 (fr) 2018-04-05
HUE070578T2 (hu) 2025-06-28
PT3518932T (pt) 2025-01-16

Similar Documents

Publication Publication Date Title
EP3488001A4 (fr) Traitement du cancer
EP3423488A4 (fr) Méthodes de traitement du cancer
EP3288383A4 (fr) Méthodes de traitement du cancer
PL3283527T3 (pl) Leczenie skojarzone nowotworów
MA43374A (fr) Méthodes de traitement de tumeurs malignes
PL3288581T3 (pl) Sposób leczenia nowotworu
IL249065A0 (en) Combination therapies for the treatment of cancer
EP3432888A4 (fr) Traitement du cancer avec tg02
IL263802A (en) Cancer treatment combinations
IL258521B1 (en) Combination therapy for the treatment of cancer
PT3458052T (pt) Tratamento combinado do cancro
MA47408A (fr) Traitement du cancer
EP3405203A4 (fr) Méthodes de traitement du cancer
MA45780A (fr) Méthodes de traitement du cancer de la prostate
EP3389634A4 (fr) Méthodes de traitement du cancer
IL265697B1 (en) Treatment of prostate cancer
EP3440112A4 (fr) Méthodes de traitement du cancer
EP3606531A4 (fr) Méthodes de traitement du cancer
PL3525774T3 (pl) Leczenie lazofoksyfenem raka piersi er+
EP3389645A4 (fr) Combinaisons pour le traitement du cancer
EP3359255A4 (fr) Polythérapies pour le traitement du cancer
LT3576740T (lt) Vėžio gydymas
EP3490561A4 (fr) Combinaisons pour le traitement du cancer
EP3442946A4 (fr) Procédés de traitement du cancer
EP3389652A4 (fr) Méthodes de traitement du cancer